To Get more Insights,  Request A Free Sample 

How Burgeoning Infertility Rate is Driving Demand for Fertility Market 

Globally, infertility affects an estimated 1 in 6 people, or 17.5% of the adult population, during their lifetime. The issue is universal, with prevalence rates showing little variation across regions, affecting 17.8% of adults in high-income countries and 16.5% in low- and middle-income nations. Male factors are a significant contributor, identified in approximately 50% of all infertility cases, either as the sole cause or in combination with female factors. This widespread need translates into millions of assisted reproductive technology (ART) cycles performed annually. Cumulatively, it is now estimated that over 10 million infants have been born worldwide from IVF.

Three Emerging Currents Shaping Tomorrow's Fertility Market

• A significant trend is the rise of direct-to-consumer diagnostics and integrated telehealth platforms. Companies are empowering individuals with at-home hormone tests and virtual consultations, shifting the initial stages of fertility assessment away from the clinic. The integration of wearable tech data with fertility apps is creating a more continuous and personalized patient experience, driving early engagement.
• Another powerful current is the mainstreaming of LGBTQ+ family-building pathways. There is a marked increase in demand for services like reciprocal IVF, directed sperm and egg donation, and gestational surrogacy in the fertility market. Clinic marketing, patient intake forms, and insurance benefit packages are rapidly evolving to be more inclusive, recognizing a diverse and growing patient demographic with unique family-planning needs.
• The automation of embryology laboratory procedures through AI and robotics is a transformative trend. Beyond embryo selection, AI is now being developed to standardize and automate tasks like sperm selection for ICSI and the annotation of time-lapse imaging. Robotic systems for vitrification and sample handling promise to reduce human error, improve consistency, and increase the overall efficiency of high-volume labs.

Oncofertility A High-Urgency and Rapidly Maturing Market Driver

The field of oncofertility represents a critical and non-discretionary driver of demand within the broader fertility market. It addresses the urgent need to preserve the reproductive potential of cancer patients facing gonadotoxic treatments like chemotherapy and radiation. The infrastructure to support these patients is growing; the Oncofertility Consortium now recognizes more than 150 global partner institutions as of 2024. This network provides crucial access to care for a vulnerable population, including very young patients. A 2024 case study highlighted the successful application of ovarian tissue cryopreservation in a patient just 18 months old, demonstrating the expanding technical capabilities in pediatric oncofertility. This clinical urgency is mirrored by significant research investment. In early 2024, the National Institutes of Health awarded a new research grant of over 450,000 dollars to study novel methods for preserving ovarian function during cancer therapy.

The demand in the fertility market is further defined by the medical community's growing commitment to establishing a clear standard of care. A pivotal 2024 international guidance paper on oncofertility was co-authored by a panel of 25 leading experts from oncology and reproductive medicine. To disseminate these standards, a specialized oncofertility webinar for healthcare providers hosted by the Alliance for Fertility Preservation in 2024 saw over 500 oncologists and nurses register. 

To alleviate financial barriers, programs like Ferring Pharmaceuticals' Heartbeat Program now offer up to 10,000 dollars in select medications for eligible patients. A 2024 report from a leading U.S. children's hospital documented over 300 pediatric fertility preservation consults in the past year. Access in the fertility market is also improving legislatively; a new California law enacted in 2024 mandates insurance coverage for the standard 10-year storage of gametes for oncofertility patients. To track outcomes, a new National Oncofertility Registry was announced in 2024, involving an initial consortium of 15 major cancer centers.

The Non-Invasive Revolution Reshaping Diagnostics and Patient Experience

A powerful force defining demand is the rapid shift towards non-invasive diagnostic technologies. Patients and clinicians in the fertility market are embracing methods that reduce physical discomfort, lower procedural risks, and provide sophisticated data with greater ease. This revolution is most evident in the area of embryo assessment. A landmark multi-center study published in early 2024 detailed the outcomes of more than 2,000 embryos analyzed using non-invasive preimplantation genetic testing (niPGT), which assesses embryonic DNA from the culture medium. The demand for less invasive approaches extends to uterine assessment. A startup that received over 5 million dollars in seed funding in 2024 is developing a new diagnostic platform based on analyzing the uterine microbiome without the need for an invasive biopsy. This approach analyzes over 200 distinct microbial biomarkers to assess uterine health.

The patient experience is being transformed by at-home, non-invasive monitoring tools. A new saliva-based hormone tracking device in the fertility market launched in 2024, with a retail price of 149 dollars, allows for daily monitoring without blood draws. In the clinic, technology is also advancing. New microfluidics-based sperm sorting chips, with a processing time of under 30 minutes, are replacing older, more time-consuming methods. Imaging is becoming more powerful; a new AI-powered follicle counting tool was recently validated using a dataset of over 50,000 ultrasound images. The precision of these tools is remarkable, with new sperm morphology imaging systems offering a resolution down to 0.5 micrometers. Demand for better diagnostics for related conditions is also growing, with over 800 patients enrolled in a 2024 clinical trial for a non-invasive blood test for endometriosis. A new high-resolution ultrasound system, with a list price of over 90,000 dollars, is now being marketed specifically for its enhanced ability to visualize endometrial receptivity markers.

Segmental Analysis

Fertility Clinics The Indispensable Core of Service Delivery

Fertility clinics with over 67% market share are the critical hubs where technology and patient care converge. Their market dominance is a direct result of being the exclusive providers of specialized services that require significant capital investment and expertise. The fact that clinics acquired by larger chains see a 27% increase in treatment cycles and a 14% rise in live birth rates points to the advantages of scale and technology adoption. As the primary consumers of advanced equipment, these clinics drive the B2B side of the fertility market. They manage complex procedures that come with substantial costs, such as laboratory fees that can reach $6,000 and PGT services costing up to $5,000.

The operational scale of these facilities is significant, with leading states like California and New York having hundreds of specialists. The expansion of employer-provided benefits, with 70% of the largest companies now covering IVF, directly channels patients into these clinical settings. This sustained patient flow, which includes around 25,000 fertility tourists annually, ensures clinics remain the largest and most crucial segment. The entire ecosystem of the fertility market revolves around the services and expertise housed within these specialized centers.

• Venture capitalists injected $345 million into fertility start-ups in 2021, many of which directly support clinic operations.
• A single IVF procedure involves over 100 distinct steps, requiring a highly controlled clinical environment.
• The annual cost for patients to store frozen embryos can be as high as $1,500 per year.

ARTs Technological Edge Propels the Global Fertility Market

Assisted Reproductive Technology's market leadership with over 72% market share is cemented by relentless innovation and tangible results. The successful execution of 432,641 IVF cycles in the U.S. alone in 2023 highlights the scale of its impact. A key driver is the increasing accessibility, partly fueled by a growing number of employers offering benefits, with some plans providing up to $75,000 in lifetime coverage. This financial support makes high-cost procedures, which can exceed $25,000 per cycle, more attainable for a broader population. The evolution of the fertility market is directly tied to ART's advancements, such as vitrification, which ensures over 90% of eggs survive thawing, making fertility preservation a viable option for the more than 40,000 individuals who chose to freeze their eggs in 2023.

The increasing trend of elective single embryo transfers, now used in over 93% of U.S. cycles, demonstrates a shift towards safer and more effective protocols. A significant investment of $33 million into a biotech firm in 2024 for new IVF technology underscores the industry's forward momentum. The fertility market benefits as these technologies mature, promising higher success rates and improved patient experiences.

• The average age for elective egg freezing has decreased to 35, indicating earlier family planning.
• Investment continues to pour into the sector, including a notable $200 million injection into a women's health application.
• Fertility tourism is a major component, with countries like India hosting over 3,000 clinics to meet international demand.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

Europe's Unrivaled Leadership in Advanced Reproductive Medicine

Europe's dominance in the global fertility market is built on a foundation of progressive regulation, high clinical standards, and significant cross-border patient flow. Spain continues to be a central hub for reproductive medicine. As of early 2024, the Spanish Fertility Society (SEF) reported that its national registry now includes data from over 350 specialized clinics. In the United Kingdom, the HFEA's 2024 report highlighted that the number of donor insemination cycles performed reached 4,891, underscoring the importance of donor services. In France, following the 2021 bioethics law update, the Agence de la biomédecine noted in its 2024 annual review that over 5,000 women had initiated the process for solo IVF or IVF with a female partner. Germany also saw a significant policy shift, with the government announcing in 2024 a new fund of 100 million euros to expand support for couples undergoing IVF.

The region's advanced infrastructure is a key asset for the fertility market. A leading Danish sperm bank, Cryos International, reported in a 2024 update that it now ships to more than 100 countries worldwide. The European Society of Human Reproduction and Embryology (ESHRE) confirmed for its 2024 annual meeting a record number of over 2,500 submitted scientific abstracts. In Italy, a 2024 ruling by the Constitutional Court expanded access to PGT for a wider range of genetic conditions. The Czech Republic's appeal as a fertility destination remains strong, with a leading Prague clinic reporting in its Q1 2024 update that it had treated patients from over 60 different countries. In Ireland, a new publicly funded IVF service launched in late 2023 saw over 3,000 couples apply within its first few months of operation into 2024. Finally, Belgium’s renowned expertise in IVM (in-vitro maturation) was highlighted at a 2024 conference, where a Brussels clinic presented data on over 800 successful IVM cycles.

North America A Powerhouse of Innovation and Corporate Investment

North America's fertility market is defined by its massive scale, high technology adoption, and a dynamic corporate landscape. In the United States, the Society for Assisted Reproductive Technology (SART) confirmed its 2024 membership now includes over 400 reporting clinics. The growth of employer-sponsored benefits continues to fuel the market; benefits manager Carrot Fertility announced in a 2024 update that it now serves over 1,000 distinct corporate clients. Canada is also expanding access, with the province of Ontario confirming in its 2024 budget the continuation of funding for over 12,000 IVF cycles annually. Investment in new technology is robust; a U.S.-based AI fertility startup, Alife Health, secured over 20 million dollars in a 2024 funding round to develop its embryology software.

The demand for specialized services is a significant driver of the fertility market. A major U.S. egg bank network reported in its 2024 quarterly statement that it now has over 15,000 donor eggs in its cryo-inventory. Reflecting the importance of male fertility, a U.S. clinic network specializing in male reproductive medicine announced in 2024 the opening of its 25th dedicated center. The cost of care remains a defining feature, with a leading New York City clinic listing its 2024 self-pay price for a single IVF cycle at over 22,000 dollars before medication. In Mexico, a prominent clinic in Cancun catering to international patients reported in early 2024 a caseload of over 500 U.S. and Canadian patients in the previous year. The legal landscape continues to evolve, with a new Colorado law passed in 2024 mandating that large group insurance plans cover up to 3 egg retrieval cycles. Finally, The Prelude Network, a major clinic consolidator, confirmed in 2024 it now employs over 250 reproductive endocrinologists across its system.

Asia Pacific A Region of Rapid Growth and Evolving Access

The Asia Pacific fertility market is characterized by rapid growth, increasing medical tourism, and a patchwork of evolving regulations. In Australia, the national ANZARD registry's latest 2024 data release confirmed that the number of infants born via ART now exceeds 18,000 annually. Japan's government, in its 2024 health budget, allocated over 30 billion yen to subsidize fertility treatments after expanding public insurance coverage. Singapore is emerging as a regional leader in technology and quality; in 2024, the Ministry of Health granted a license to the nation's 15th approved ART clinic. In India, the Assisted Reproductive Technology (Regulation) Act continues to be implemented, with a 2024 government report indicating that over 1,200 clinics have now received formal registration.

The demand for cross-border services is high. Thailand's Board of Investment announced in a 2024 statement new incentives for building medical wellness centers, including fertility clinics, which treated over 50,000 international patients for various services last year. In South Korea fertility market, a leading Seoul clinic reported in 2024 that it has performed over 1,000 PGT-A cycles since the procedure was re-authorized. China's National Health Commission stated in a 2024 directive a goal to have over 650 licensed ART institutions operating by the end of the year. In Malaysia, a prominent fertility group announced the 2024 opening of its 15th center in the country. Vietnam is also a rising star, with a major Ho Chi Minh City hospital reporting in 2024 that its ART unit now performs over 3,000 IVF cycles per year. Lastly, in Taiwan, the government confirmed in a 2024 health update that its IVF subsidy program has supported over 20,000 treatment courses since its inception.

Top 10 Investment Heats Up in the Fertility Market With Landmark 2024 Deals

1. Alife Health Secures $22 Million in Funding
   The fertility AI startup Alife Health, which develops software to optimize IVF, announced a successful Series A funding round of 22 million dollars.
2. Xytex and Donor Egg Bank USA Merge
   Two major players in third-party reproduction, cryobank Xytex and Donor Egg Bank USA, announced a strategic merger to create a more comprehensive service platform.
3. Gameto Raises $33 Million for Ovarian Therapeutics
   Biotechnology company Gameto, which focuses on female reproductive longevity, closed a 33 million dollar Series B funding round to advance its ovarian treatment platform.
4. Orchid Raises $36 Million for Genetic Screening
   Orchid, a company specializing in pre-conception genetic screening for couples, announced a new 36 million dollar funding round to expand its testing services.
5. Ro Acquires Legacy to Enter Male Fertility Market
   Digital health company Ro acquired Legacy, a leading provider of at-home sperm testing and cryopreservation, marking a major entry into the male fertility space.
6. Future Family Secures $9 Million for Fertility Financing
   Fintech company Future Family, which offers financing plans for fertility treatments, raised 9 million dollars in a new funding round to expand its loan offerings.
7. Summa Equity Acquires Majority Stake in Axcelerate
   European private equity firm Summa Equity acquired a majority stake in Axcelerate, a provider of specialized embryology and andrology lab services in the UK.
8. TMRW Life Sciences Partners with Boston IVF
   Fertility technology company TMRW, known for its automated cryo-management platform, announced a major partnership to install its system in the Boston IVF network.

Top Companies in the Fertility Market

• Apricity Fertility UK Limited
• Aspire Fertility
• Care Fertility
• Cleveland Clinic
• Dallas IVF
• Europe IVF
• King’s Fertility Limited
• Mayo Foundation for Medical Education and Research (MFMER)
• Midwest Fertility Specialists
• Monash IVF Group
• Virtus Health
• PFCLA
• Other Prominent Players

Market Segmentation Overview

By Offering

• Fertility Drugs
  • Anti-estrogen
  • Gonadotropin
  • Others
• Assisted Reproductive Technology
  • Artificial Insemination
  • Surrogacy
  • IVF
  • Others

By End user

• Clinical Research Institutes
• Fertility Clinics
• Hospitals

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America